The global acral lentiginous melanoma drugs market is projected to have a considerable CAGR during the forecast period. Melanoma that develops on the palms or soles is known as acral lentiginous melanoma. Acral lentiginous melanoma begins as a flat area of discoloured skin that progressively grows in size. The malignant cells initially remain inside the origin tissue, the epidermis that is known as the in situ phases of melanoma, and it can last for months or years. Melanoma cells breach the epidermis' basement membrane and enter the dermis, causing acral lentiginous melanoma to become invasive. Acral lentiginous melanoma can potentially develop into a fast-growing nodular melanoma that spreads deeper into the skin.

According to the National Center for Biotechnology Information, acute lentiginous melanoma accounts for around 2%-3% of all melanomas. When compared to Whites, the total prevalence of cutaneous malignant melanoma in darker-skinned people is modest. Acute Lentiginous Melanoma accounts for a considerably greater proportion of cutaneous malignant melanoma in darker-skinned people (i.e, Blacks, Asians, and Hispanics). The patients had an average three-year survival rate of 11%. The low survival percentage of acute lentiginous melanoma patients might be attributed in part to diagnostic delays. Thus, the rising incidences of acute lentiginous melanoma in coloured individuals will drive the market for global acral lentiginous melanoma drugs.

Another driving factor for the market is the increasing research on pipeline drugs. P PSMA 101, Autologous adipose-derived mesenchymal stem cell treatment, EPI 7386, ODM 208, MCS 8, ADXS PSA, Exicorilant, and VERU-100 are all new pipeline items. Vaccitech is working on a ChAdOx1-MVA 5T4 vaccine (VTP-008). This vaccination will be administered in combination with nivolumab, an anti-PD-1 (Programmed Death Protein-1) monoclonal antibody used in immunotherapy. Furthermore, in October 2020, Foresee Pharmaceuticals reported that the FDA has accepted its New Drug Application (NDA) for FP-001 LMIS 50mg, or CAMCEVI 42MG, a ready-to-use 6-month depot formulation of leuprolide mesylate, for evaluation.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered

• Regions Covered

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape: AbbVie Inc., Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Johnson & Johnson, Merck & Co.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Acral Lentiginous Melanoma Drugs Market by Therapy

• Chemotherapy
• Targetted Therapy
• Immuno Therapy

Global Acral Lentiginous Melanoma Drugs Market by Region